FDA Approves Jaypirca as First-Line CLL/SLL Therapy, Expanding Lilly's Oncology Reach
LLY sits 46% above its 52-week low of $783.845 on light trading volume (0.2× avg).
Summary
The FDA approved Jaypirca (pirtobrutinib) for first-line treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma without 17p deletion. This is a significant label expansion for Lilly's non-covalent BTK inhibitor, making it the first and only approved drug in its class for this indication. Phase 3 BRUIN CLL-313 data showed a hazard ratio of 0.20 for progression-free survival versus bendamustine plus rituximab, with an overall response rate of 94% and median PFS not yet reached. The approval opens a large patient population and strengthens Lilly's oncology franchise, which has been overshadowed by its diabetes and obesity portfolio. Shares rose 1.68% on the news, reflecting modest but positive market reaction. Watch for commercial launch details and potential NCCN guideline updates that could drive adoption.
At the time of this announcement, LLY was trading at $1,144.98 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $783.85 to $1,292.65. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Benzinga.